Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SafeHER: SC Trastuzumab in Early HER2+ Breast Cancer
NCT01566721Phase 3Completed
- Sponsor
- Roche
- Start
- May 2012
- Primary completion
- Mar 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 59
01
Overview
Phase 3, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With At Least 1 Adverse Event at 1 year, Percentage of Participants With a Grade 3 or Higher AE at 1 year and 2 more. Started May 2012; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01566721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01566721.